Business Segments Sino Biopharmaceutical Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 20/05/2026 pm IST			5-day change	1st Jan Change
5.170 ^HKD	-1.34%		-10.55%	-16.34%

11/05	Global markets live: Alphabet, Cerebras, Compass, GSK, Rockwool…
11/05	Hong Kong Stocks Little Changed as U.S.-Iran Talks Remain Deadlocked; LDROBOT Gains on Debut	MT

Breakdown by Business Segment (HKD)

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Pharmaceutical Products
Pharmaceuticals	-	-	-	-	3.18TCr
Total Assets	-	-	-	-	7.6TCr
Interest Expense	-	-	-	-	-28Cr
Income Tax Expense	-	-	-	-	162.89Cr
CAPEX	-	-	-	-	-123.88Cr
EBT	-	-	-	-	694.34Cr
Gross Profit	-	-	-	-	2.61TCr
D&A	-	-	-	-	104.15Cr
Net Income	-	-	-	-	234.33Cr
Modernised Chinese Medicines and Chemical Medicines	2.62TCr	2.82TCr	2.58TCr	2.85TCr	-
Total Assets	3.25TCr	3.93TCr	4.05TCr	4.3TCr	-
CAPEX	-148.63Cr	-174.27Cr	-	-	-
Gross Profit	-	-	-	2.34TCr	-
D&A	90Cr	101.41Cr	100.52Cr	121.62Cr	-
Operating Income	523.42Cr	691.38Cr	652.52Cr	560.92Cr	-
Total Assets	1.43TCr	1.32TCr	1.22TCr	162.01Cr	-
Total Assets	-	-	91Cr	-	-
Total Assets	33Cr	51Cr	57Cr	52Cr	-
Hospitals and Healthcare Centers
Others	63Cr	55Cr	43Cr	40Cr	-
Total Assets	164.43Cr	161.02Cr	160.07Cr	157.72Cr	-
CAPEX	-6Cr	-89.38L	-	-	-
D&A	4.06Cr	1.86Cr	1.67Cr	5.41Cr	-
Operating Income	10Cr	7.78Cr	1.99Cr	7.61Cr	-
Investment Funds
Operating Income	-15Cr	-78Cr	-41Cr	-26Cr	-
D&A	5.6Cr	1.43Cr	1.47Cr	5.1Cr	-
CAPEX	-1.49Cr	-83.26L	-	-	-
Gross Profit	-	-	-	7.99Cr	-
Total Assets	1.18TCr	946.32Cr	779.17Cr	1.87TCr	-

Geographical breakdown of sales (HKD)

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Mainland China	2.69TCr	2.88TCr	2.62TCr	2.89TCr	3.18TCr
Total Assets	1.87TCr	1.8TCr	1.62TCr	1.15TCr	7.6TCr
Interest Expense	-	-	-	-	-
Income Tax Expense	-	-	-	-	-
D&A	-	-	-	-	-
CAPEX	-	-	-	-	-
Gross Profit	-	-	-	-	-
Net Income	-	-	-	-	-
EBT	-	-	-	-	-
Total Assets	675.06Cr	724.11Cr	898.76Cr	356.76Cr	-
Total Assets	34Cr	38Cr	43Cr	39Cr	-